Mutational Analysis of BRCA1/2 in Ovarian Cancer Patients
12 Aug 2019
At the European Society of Human Genetics (ESHG) conference 2019, Dr. Bartosz Wasag, Medical University of Gdansk & University Clinical Centre, Gdansk, Poland, presents a cost-effective, highly-sensitive approach for the analysis of variants in breast and ovarian cancer-associated BRCA1 and BRCA2 genes. Using amplicon-based next-generation sequencing (NGS) technology from Agilent Technologies, this approach may be applicable for routine diagnostics in the future.
Related Products
Request Quote for All Products
SureSelect Human All Exon Kits
Agilent TechnologiesAgilent SureSelect All Exon kits are the most widely used target enrichment solution for exome sequencing. SureSelect Human All Exon V5 (targeting coding regions only) and V5+UTRs (targeting coding regions plus UTRs) have been updated to provide the greatest sequencing efficiency and enable samples ready for sequencing the next day. Greater coverage with less sequencing for lower overall costs – up to 60% less sequencing than other exomes Samples ready for sequencing the next day – short 16 hour overnight hybridization Fast turnaround time for your exome projects – the most samples per sequencing run
